The combination therapy with alfacalcidol and risedronate improves the mechanical property in lumbar spine by affecting the material properties in an ovariectomized rat model of osteoporosis

BMC Musculoskeletal Disorders

Volumn 10, Issue 1, 2009, Pages

  Shiraishi, Ayako ^a   Miyabe, Sayaka ^b   Nakano, Takayoshi ^b   Umakoshi, Yukichi ^b   Ito, Masako ^c   Mihara, Masahiko ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c NAGASAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALFACALCIDOL; APATITE; BIOCHEMICAL MARKER; CALCIUM; CREATININE; PHOSPHATE; RISEDRONIC ACID; 1-HYDROXYCHOLECALCIFEROL; BIOLOGICAL MARKER; BONE DENSITY CONSERVATION AGENT; DRUG DERIVATIVE; ETIDRONIC ACID; HYDROXYAPATITE; HYDROXYCOLECALCIFEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METABOLISM; BONE STRENGTH; BONE STRUCTURE; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CALCIUM URINE LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; FEMALE; FEMUR SHAFT; LUMBAR SPINE; LUMBAR VERTEBRA; MICRO-COMPUTED TOMOGRAPHY; MONOTHERAPY; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; PHOSPHATE BLOOD LEVEL; PHOSPHATE URINE LEVEL; SHAM FEEDING; THERAPY EFFECT; X RAY DIFFRACTION; ANIMAL; BIOMECHANICS; BLOOD; BONE DENSITY; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECT; DRUG POTENTIATION; FEMUR; HUMAN; MECHANICAL STRESS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; RADIOGRAPHY; RAT; TREATMENT OUTCOME; URINE; WEIGHT BEARING; WISTAR RAT;

ANIMALS; BIOLOGICAL MARKERS; BIOMECHANICS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; DURAPATITE; ETIDRONIC ACID; FEMALE; FEMUR; HUMANS; HYDROXYCHOLECALCIFEROLS; LUMBAR VERTEBRAE; OSTEOPOROSIS, POSTMENOPAUSAL; OVARIECTOMY; RATS; RATS, WISTAR; STRESS, MECHANICAL; TREATMENT OUTCOME; WEIGHT-BEARING; X-RAY DIFFRACTION; X-RAY MICROTOMOGRAPHY;

EID: 68149181012     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-10-66     Document Type: Article

References (40)

1. Consensus development conference, prophylaxis and treatment of osteoporosis. Am J Med 1991 90 107 110 10.1016/0002-9343(91)90512-V 1986575
2. Changes in bone mineral density of the proximal femur and spine with aging. Differences between the postmenopausal and senile osteoporosis syndromes. BL Riggs HW Wahner E Seeman KP Offord WL Dunn RB Mazess KA Johnson LJ Melton, J Clin Invest 1982 70 716 723 7119111 10.1172/JCI110667
3. Effects of 1 hydroxy-vitamin D 3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. H Orimo M Shiraki Y Hayashi T Hoshino T Onaya S Miyazaki H Kurosawa T Nakamura N Ogawa, Calcif Tissue Int 1994 54 370 376 10.1007/BF00305521 8062152
4. Effects of 2 year's treatment of osteoporosis with 1 hydroxy-vitamin D 3 on bone mineral density and incidence of fracture: a placebo-controlled, double blind prospective study. M Shiraki K Kushida K Yamazaki, Endocine J 1996 43 211 220 10.1507/endocrj.43.211
5. The effects of ovariectomy and 17-estradiol on cortical bone histomorphometry in growing rats. RT Turner JJ Vandersteenhoven NH Bell, J Bone Miner Res 1987 2 115 122 3455160
6. Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct actions from estrogen. A Shiraishi S Takeda T Masaki Y Higuchi Y Uchiyama N Kubodera K Sato K Ikeda T Nakamura T Matsumoto E Ogata, J Bone Miner Res 2000 15 4 770 779 10.1359/jbmr.2000.15.4.770 10780869
7. Pharmacokinetics of alendronate. AG Porras SD Holland B Gertz, Clin Pharmacokinet 1999 36 315 328 10.2165/00003088-199936050-00002 10384857 (Pubitemid 29261508)
8. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume. P Fratzl P Roschger N Fratzl-Zelman EP Paschalis R Phipps K Klaushofer, Calcif Tissue Int 2007 81 2 73 80 10.1007/s00223-007-9039-8 17612779 (Pubitemid 47240833)
9. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. T Dufresne P Chmielewski M Manhart T Johnson B Borah, Calcif Tissue Int 2003 73 423 432 10.1007/s00223-002-2104-4 12964065 (Pubitemid 37466634)
10. Bisphosphonates: mechanisms of action. GA Rodan HA Fleisch, J Clin Invest 1996 97 2692 2696 8675678 10.1172/JCI118722
11. Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women. R Zoehrer P Roschger EP Paschalis JG Hofstaetter E Durchschlag P Fratzl R Phipps K Klaushofer, J Bone Miner Res 2006 21 7 1106 1112 10.1359/jbmr.060401 16813531 (Pubitemid 43962839)
12. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. GY Boivin PM Chavassieux AC Santora J Yates PJ Meunier, Bone 2000 27 687 694 10.1016/S8756-3282(00)00376-8 11062357 (Pubitemid 30808808)
13. Bone material properties and mineral matrix contributions to fracture risk or age in women and men. DB Burr, J Musculoskelet Neuronal Interact 2002 2 201 204 15758433
14. Contribution of bone mineral density and bone turnover markers to the estimation of risk of Osteoporotic fracture in postmenopausal women. P Gearnero PD Delmas, J Musculoskelet Neuronal Interact 2004 4 50 63 15615078
15. Bone fragility and collagen cross-links. EP Paschalis E Shne D Lyritis G Skaeantavos R Mandelsohn AL Boskey, J Bone Miner Res 2004 19 2000 2004 15537443 10.1359/JBMR.040820 (Pubitemid 41109925)
16. Unique alignment and texture of biological apatite crystallites in typical calcified tissues analyzed by micro-beam X-ray diffractometer system. T Nakano K Kaibara Y Tabata N Nagata S Enomoto E Marukawa Y Umakoshi, Bone 2002 31 479 487 10.1016/S8756-3282(02)00850-5 12398943 (Pubitemid 35175451)
17. Texture and Bone Reinforcement. T Nakano Y Tabata Y Umakoshi, Encyclopedia of Materials, Science and Technology Updates, Elsevier, Oxford 2005 MS2061-1-8.
18. Alendronate treatment promotes bone formation with a less anistropic microstructure during intramembranous ossification in rats. M Kashii J Hashimoto T Nakano Y Umakoshi H Yoshikawa, J Bone Miner Metab 2008 26 24 33 10.1007/s00774-007-0782-8 18095060 (Pubitemid 350307995)
19. The strength of a calcified tissue depends in part on the molecular structure and organization of its constituent mineral crystals in their organic matrix. WJ Landis, Bone 1995 16 533 544 10.1016/8756-3282(95)00076-P 7654469
20. X-ray pole figure analysis of apatite crystals and collagen molecules in bone. N Sasaki Y Sudoh, Calcif Tissue Int 1997 60 361 367 10.1007/s002239900244 9075634 (Pubitemid 27143451)
21. Plastic Deformation and operative slip system in mineral fluorapatite single crystals. T Nakano T Awazu Y Umakoshi, Scripta Materialia 2001 44 811 815 10.1016/S1359-6462(00)00656-4 (Pubitemid 32303013)
22. Texture, stress, and age in the human femur. GE Bacon RK Griffiths, Journal of Anatomy 1985 143 97 101 3870736
23. Areal distribution of preferential alignment of biological apatite (BAp) crystallite on cross-section of center of femoral diaphysis in osteopetrotic (op/op) mouse. JW Lee T Nakano S Toyosawa Y Tabata Y Umakoshi, Materials Transactions 2007 48 337 342 10.2320/matertrans.48.337 (Pubitemid 46642243)
24. The effects of aging and ovariectomy on the vertebral bone mass and biomechanical properties of mature rats. L Mosekilde CC Danielsen UB Knudsen, Bone 1993 14 1 6 10.1016/8756-3282(93)90248-9 8442996
25. Intermittent cyclical etidronate treatment maintains the mass, structure and the mechanical property of bone in ovariectomized rats. T Katsumata T Nakamura H Ohnishi T Sakurawa, J Bone Miner Res 1995 10 921 931 7572316
26. Accuracy of cortical and trabecular bone measurements with peripheral quantitative computed tomography (pQCT). P Augat CL Gordon TF Lang H Iida HK Genant, Phys Med Biol 1998 43 10 2873 2883 10.1088/0031-9155/43/10/015 9814524 (Pubitemid 28474191)
27. Regional Analysis of Bone Mineral Density in the Distal Femur and Proximal Tibia Using Peripheral Quantitative Computed Tomography in the Rat In Vivo. SA Breen AJ Millest BE Loveday D Johnstone JC Waterton, Calcif Tissue Int 1996 58 6 449 453 8661488
28. Analysis of trabecular microarchitecture of human iliac bone using microcomputed tomography in patients with hip arthrosis with or without vertebral fracture. M Ito T Nakamura T Matsumoto K Tsurusaki K Hayashi, Bone 1998 23 163 169 10.1016/S8756-3282(98)00083-0 9701476 (Pubitemid 28379878)
29. Direct three-dimensional morphometric analysis of human cancellous bone: microstructural data from spine, femur, iliac crest, and calcaneous. T Hildebrand A Laib R Muller J Dequeker P Ruegsegger, J Bone Miner Res 1999 14 1167 1174 10.1359/jbmr.1999.14.7.1167 10404017 (Pubitemid 29314060)
30. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. DE Hughes KR Wright HL Uy A Sasaki T Yoneda GD Roodman GR Mundy BF Boyce, J Bone Miner Res 1995 10 1478 1487 8686503
31. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT Research Group. DM Black DE Thompson DC Bauer K Ensrud T Musliner MC Hochberg MC Nevitt S Suryawanshi SR Cummings, J Clin Endocrinol Metab 2000 85 4118 4124 10.1210/jc.85.11.4118 11095442 (Pubitemid 32055362)
32. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. ST Harris NB Watts HK Genant CD McKeever T Hangartner M Keller CH Chesnut III J Brown EF Eriksen MS Hoseyni DW Axelrod PD Miller, JAMA 1999 282 1344 1352 10.1001/jama.282.14.1344 10527181 (Pubitemid 29483192)
33. Structure and mechanical quality of the collagen-mineral nano-composite in bone. P Fratzl HS Gupta EP Paschalis P Roschger, J Mater Chem 2004 14 2115 2123 10.1039/b402005g
34. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. B Borah TE Dufresne EL Ritman SM Jorgensen S Liu PA Chmielewski RJ Phipps X Zhou JD Sibonga RT Turner, Bone 2006 39 2 345 352 10.1016/j.bone.2006.01.161 16571382 (Pubitemid 43851366)
35. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume. P Fratzl P Roschger N Fratzl-Zelman EP Paschalis R Phipps K Klaushofer, Calcif Tissue Int 2007 81 2 73 80 10.1007/s00223-007-9039-8 17612779 (Pubitemid 47240833)
36. Direct stereological estimation of three-dimensional connectivity in rat vertebrae: effect of estrogen, etidronate and risedronate following ovariectomy. RW Boyce TJ Wronski DC Ebert ML Stevens CL Paddock T Youngs HJ Gundersen, Bone 1995 16 2 209 213 10.1016/8756-3282(94)00031-T 7756049
37. Prevention of bone loss in ovariectomized rats by combined treatment with risedronate and 1alpha, 25-dihydroxyvitamin D 3. RG Erben L Mosekilde JS Thomsen K Weber K Stahr A Leyshon SY Smith R Phipps, J Bone Miner Res 2002 17 8 1498 1511 10.1359/jbmr.2002.17.8.1498 12162504
38. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. ST Harris EF Eriksen M Davidson MP Ettinger AH Moffett Jr DJ Baylink CE Crusan AA Chines, J Clin Endocrinol Metab 2001 86 1890 1897 10.1210/jc.86.5.1890 11344179 (Pubitemid 32472892)
39. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. DM Black SL Greenspan KE Ensrud L Palermo JA McGowan TF Lang P Garnero ML Bouxsein JP Bilezikian CJ Rosen PaTH Study Investigators, N Engl J Med 2003 349 1207 1215 10.1056/NEJMoa031975 14500804 (Pubitemid 37152030)
40. The effects of nitrogen-containing bisphosphonates on human epithelial (Caco-2) cells, an in vitro model for intestinal epithelium. IM Twiss O Pas W Ramp-Koopmanschap J Den Hartigh P Vermeij, J Bone Miner Res 1999 14 784 791 10.1359/jbmr.1999.14.5.784 10320527 (Pubitemid 29210605)